First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.
Frequently asked questions
What sector does First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) operate in?
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued belongs to the Other sector and operates in the Biotechnology industry.
What is First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) current stock price?
As of the latest data, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued stock price is $17.66, with a previous close of $17.66.
What is First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) current market capitalization?
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued market cap is approximately 613.49 million.
Does First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) pay dividends?
No. First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued does not pay a dividend.
What is First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) beta (volatility) score?
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued has a beta of -0.050, indicating lower volatility than the overall market.
